Jakob Loven is a seasoned Managing Partner at Nextech Invest Ltd., with a strong background in biotechnology and life sciences. He serves on multiple boards, including A2 Biotherapeutics, Arrakis Therapeutics, and Boundless Bio, showcasing his expertise in the industry. Jakob's research on MYCN-driven miRNAs in neuroblastoma patients has been published in reputable journals, highlighting his contr...